PERMAX Drug Patent Profile
✉ Email this page to a colleague
When do Permax patents expire, and what generic alternatives are available?
Permax is a drug marketed by Valeant Pharm Intl and is included in one NDA.
The generic ingredient in PERMAX is pergolide mesylate. There are four drug master file entries for this compound. Additional details are available on the pergolide mesylate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PERMAX?
- What are the global sales for PERMAX?
- What is Average Wholesale Price for PERMAX?
Summary for PERMAX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,948 |
| DailyMed Link: | PERMAX at DailyMed |
Recent Clinical Trials for PERMAX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Colorado Neurology | Phase 3 |
| Agarwal, Pinky, M.D. | Phase 3 |
| GlaxoSmithKline | Phase 3 |
US Patents and Regulatory Information for PERMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-001 | Dec 30, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-002 | Dec 30, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-003 | Dec 30, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PERMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-003 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-001 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-001 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PERMAX
See the table below for patents covering PERMAX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ireland | 61960 | Stabilized pergolide compositions | ⤷ Sign Up |
| Belgium | 873883 | ⤷ Sign Up | |
| Hungary | 200691 | PROCESS FOR STABILIZATION AGAINST DECOMPOSITION CAUSED BY LIGHT, OF STABILIZED PERGOLID COMPOSITIONS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PERMAX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0003667 | SPC/GB93/063 | United Kingdom | ⤷ Sign Up | SPC/GB93/063, EXPIRES: 20040204 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
